MissionIRNewsBreaks – SRAX Inc. (NASDAQ: SRAX) 2019 Holiday-Spending Report Demonstrates Proprietary BIGtoken Platform’s Capability

Digital-marketing and consumer-data-management technology company SRAX (NASDAQ: SRAX) recently revealed results from its 2019 Holiday Spending Report (http://ibn.fm/1KD3A). SRAX COO Kristoffer Nelson said the survey of 116,000 American consumers confirms the power of its proprietary BIGtoken platform. An article discussing the company reads, “The survey showed that 28% of American consumers polled planned to holiday shop in stores, while 40% planned online purchases and 32% said they would buy both in store and online. Results from the 2019 Holiday Spending Report by SRAX also breaks down results by gender, age, ethnicity and household income. Cyber Monday and Black Friday data results are also specified. . . . ‘We are happy to freely share the latest BIGresearch results,’ Nelson said in a news release. ‘Topical surveys such as this demonstrate the power of our platform to quickly and accurately gather insights from specific audiences.’”

To view the full article, visit http://ibn.fm/ueFr1

About SRAX Inc.

SRAX is a digital-marketing and consumer-data-management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and the characteristics of those consumers across marketing channels. Monetizing its data sets, SRAX is growing multiple, recurring revenue streams through various platforms. Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby offering everyone in the internet ecosystem choice, transparency and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor-relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Announces Q2 2019 and First Half 2019 Unaudited Financial Results

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a producer, developer and operator of augmented reality (“AR”) interactive entertainment games, toys and educational materials in China, today announced its unaudited financial results for the fiscal quarter and six months ended June 30, 2019. Among the highlights, BHAT reported* a total revenue increase of 74.6% year-on-year to $3.2 million for the second quarter of 2019, as well as a total revenue increase of 11.9% year-on-year to $7.5 million for the first half of 2019. “We are delighted to report strong sales momentum and healthy profitability for our first earnings since becoming a NASDAQ-listed company,” Blue Hat CEO Xiaodong Chen said in the news release. “During the first half of 2019 we expanded our product portfolio and marketing reach, with particular highlights including our partnership with the ‘Talking Tom and Friends’ media franchise to produce new branded version of our products, the launch of an upgraded model of ‘Crazy Bug’** and distribution agreements with leading national toy retailers. We also completed research and development on our AR Bouncing Bubble and AR Dinosaur products. Looking ahead, we intend to continue to strengthen our pipeline of innovative toys and game content through both in-house development and potential strategic acquisitions, although no definitive agreements have been executed.”

To view the full press release, visit http://ibn.fm/6oM2K

About Blue Hat

Blue Hat Interactive Entertainment Technology is a producer, developer and operator of AR interactive entertainment games and toys in China, including interactive educational materials, mobile games, and toys with mobile game features. The company’s interactive entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, visit the company’s website at www.BlueHatGroup.net.

* The average translation rates applied to statement of income accounts for the periods ended June 30, 2019 and 2018 were 6.79 RMB and 6.37 RMB to $1.00, respectively. The balance sheet amounts as of June 30, 2019 and December 31, 2018 were translated at 6.87 RMB and 6.62 RMB, respectively.

** “Crazy Bug” was the classic model of “AR Crazy Bug”, which was previously named “AR Need a Spanking”.

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Sigma Labs, Inc. (NASDAQ: SGLB) to Present at February’s Imperial Capital Advanced Manufacturing & Supply Chain Conference

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D printing industry, today announced that it has been invited to present at the Imperial Capital Advanced Manufacturing & Supply Chain Conference. According to the update, the event is slated to be held at the Hyatt Regency in Huntington Beach, California on February 12-13, 2020. Sigma Labs CEO John Rice will present on the Additive Manufacturing Technologies & Services panel scheduled to take place on February 13 from 9:00 – 9:50 AM PST, as well as host one-on-one meetings throughout the day.

To view the full press release, visit http://ibn.fm/atilX

About Sigma Labs

Sigma Labs, Inc. (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D printing industry under the PrintRite3D(R) brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (CAI) solutions known as PrintRite3D(R) for 3D advanced manufacturing technologies. Sigma Labs’ advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance mid-production, uniquely allowing errors to be corrected in real-time. For more information, please visit www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Pressure BioSciences, Inc. (PBIO) Announces Plans to Release Benchtop UST-Based BaroShear Instrument in Q3 2020

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced its plans to release a benchtop, R&D scale, Ultra Shear Technology(TM) (“UST”)-based BaroShear instrument to the market in the third quarter of 2020. Per the update, Pressure BioSciences believes this new instrument will address a significant un-met need in product formulation and development laboratories throughout cannabis, cosmetics, nutraceuticals, pharmaceuticals, and other large and diverse markets for processing CBD and other oils into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water. “We are very excited about the planned release later this year of the third instrument in the BaroShear product family. The aggressive marketing campaign we have underway for the pre-sale of our BaroShear K45 system and for the 2021 release of our industrial-scale BaroShear Max instrument has been well received by manufacturing laboratories,” Director of PBI’s UST Program, Kenneth F. Micciche, said in the news release. “However, it has become apparent that product research and development labs prefer a smaller, bench-top, lower price-point, minimal throughput UST-based instrument. The BaroShear Mini clearly answers that need and will do so without cannibalizing sales to larger manufacturing facilities.  We believe this new instrument will add significantly to PBI’s revenue in 2020.”

To view the full press release, visit http://ibn.fm/Q5sSB

About Pressure BioSciences Inc.

Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the biopharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Accelerates Delivery of CBD into Bloodstream

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) 2.0 version of its patented DehydraTECH(TM) oral drug-delivery technology has demonstrated its power to deliver more cannabidiol (“CBD”) into the bloodstream than generic industry-control formulations (http://ibn.fm/Utl7A). An article discussing the company reads, “The company’s 2.0 technology is specifically being developed for effectiveness in helping to deliver its drug payload across the blood-brain barrier, a natural biological system of blood vessels and endothelial cells that bar most drugs from accessing the brain’s central-nervous-system hierarchy. The ability to effectively deliver drugs to the brain is of keen interest to developers of drugs designed to beneficially target the central nervous system. . . . Lexaria’s research and development showed that DehydraTECH version 2.0 was able to deliver 1,937% more CBD into brain tissue than generic industry-control formulations and 487% more than the original DehydraTECH technology, according to the company’s news release.”

To view the full article, visit http://ibn.fm/4HHq5

About Lexaria Bioscience Corp.

Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Sigma Labs Inc.’s (NASDAQ: SGLB) Breakthrough 3D-Printing Technology Could Play Key Role in Burgeoning Automotive Space

• Additive manufacturing for automotive production expected to reach nearly $10 billion in yearly sales by 2030
• Forecasts based primarily on automotive 3D-printing, end-use parts production
• SGLB’s proprietary, real-time, computer-aided, inspection technology enables nondestructive quality assurance during production process

Forecast to see explosive growth in the automotive industry by the year 2030, additive manufacturing (3D printing) provides numerous benefits to auto manufacturers. Much of the anticipated growth is expected to come from end-use parts production, an area where Sigma Labs Inc. (NASDAQ: SGLB), the only known producer of quality assurance software for the commercial 3D-printing industry, may provide significant advantages.

A recent 3D Printing Media Network article by Davide Sher reported that “all revenue streams associated to AM for automotive production (not including prototyping) are now expected to add up to nearly $10 billion in total yearly sales by the end of this decade.” This graph illustrates the phenomenal growth projections (http://ibn.fm/lpIZR).

These projections are based primarily on automotive 3D-printing in end-use parts production, which industry experts say is now fully within reach and is going to enable additive manufacturing to finally scale up. The term “end-use parts” indicates both final automotive parts and tools, including molds, dies, jigs and fixtures as well as custom assembly tools that are used in the automotive production process.

Even with the $10-billion industry forecast, the 3D Printing Media Network article noted that the value proposition for additive manufacturing in automotive mass production may still be difficult to accurately quantify. “The difference is that until a few years ago, this value proposition was almost nonexistent (except for prototyping and some tooling),” wrote Sher. “Now the value proposition exists, and its potential is very significant.”

Sigma Labs is well positioned to exploit and help support the forecast burgeoning growth of 3D metal printing in the automotive space. An industry pioneer and leader in 3D printing software, Sigma Labs has developed a proprietary, real-time, computer-aided, inspection (CAI) technology, PrintRite3D(R), that enables nondestructive quality assurance during the production process. Representing a breakthrough in technology, PrintRite3D is the only real-time, in-process, quality-assurance software for the commercial 3D metal printing industry. With explosive potential of 3D printing in the automotive space, SGLB’s revolutionary technology could be an essential catalyst of the expected growth.

Sigma Labs was founded in 2010 and has since become the go-to, 3D-printing expert for real-time, computer-aided inspection (CAI) solutions. Managed by experts from many different science disciplines such as metallurgy, physics, signal processing, mechanical engineering, optics, software AI and ML, data analytics and visualization, the company has established credibility and efficacy within highly demanding industries such as aerospace, defense, biomedical and transportation.

The 3D Printing Media Network article attributes the tremendous industry potential in part to manufacturers of “traditional” additive-manufacturing technologies for both polymers and metals working to optimize the end-to-end, 3D-printing production process. That optimization stems from introducing additional elements of automation, improving software that runs the AM process and developing new designs that take full advantage of AM technologies.

“The reason why [manufacturers] finally did this is that the pressure is on from a number of new entry AM firms (HP, Carbon, Desktop Metal) that have been introducing faster and more cost-effective processes, the so-called planar processes, specifically with automotive mass production in mind,” said Sher. “The implications of this ‘clash of titans’ will be seen more clearly over the next decade, but my opinion is that this will greatly benefit adoption, pushing large automotive firms to continue to invest large sums of money even if the short-term financial benefits from AM applications are not as immediately clear as they may be in other segments.”

At the forefront of this incredible manufacturing revolution, Sigma Labs could easily find its one-of-kind software integrated into the 3D manufacturing process throughout the automotive industry.

For more information, visit the company’s website at www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Independent Research Findings on TUSC2 as a Potential Target and Biomarker for Thyroid Carcinoma

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that, in a recent study, independent researchers reported that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex(TM) immunogene therapy, is a potential target and biomarker for thyroid carcinoma. Genprex has no affiliation with these researchers. The study, published in the International Journal of Molecular Sciences, reports that TUSC2 overexpression decreased thyroid cancer proliferation, migration and invasion. “We continue to be encouraged by data resulting from studies conducted at multiple research institutions suggesting that TUSC2 may be an effective treatment for many types of cancer, now including thyroid cancer,” Genprex Chairman and Chief Executive Officer Rodney Varner said in the news release.

To view the full press release, visit http://ibn.fm/X5uiL

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform. Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. The company’s lead product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (“NSCLC”), has a multimodal mechanism of action whereby it has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells, re-establish pathways for apoptosis, or programmed cell death, in cancer cells, and modulate the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. In January 2020, the FDA granted Fast Track Designation for Oncoprex(TM) imunogene therapy for NSCLC in combination therapy with AstraZeneca’s Tagrisso(R). For more information, please visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Unique Competitive Advantage

Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company, possesses a unique advantage over its competition in the form of samples and access to historical data on clinical outcomes. This data could enable POAI to produce value to pharmaceutical companies significantly faster than its competitors. An article discussing the company reads, “Specifically, POAI can leverage two unique proprietary assets, from its acquisition of Helomics, which virtually eliminate development risk, a factor that considerably weighs on competitors’ efforts in the precision medicine space. First, Predictive Oncology possesses a clinically validated, tumor-profiling platform built from data derived from actual tumors collected from patients over more than 10 years, which was clinically validated in ovarian cancer. Second, the company possesses data on the drug-response profiles of over 150,000 tumors across 137 cancer types tested over the same period. Using this valuable historical data, POAI’s platform can help predict drug response and outcome of the specific type of tumor collected from new patients, thus improving the patient outcomes.”

To view the full article, visit http://ibn.fm/iizsM

About Predictive Oncology

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient-derived (PDx) smart tumor-profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Sigma Labs Inc. (NASDAQ: SGLB) Software Possible Key to Growing Use of 3D Printing in World of Auto Making

• Numerous companies, including Volkswagen, BMW and Jaguar Land Rover, are piloting and deploying 3D-printing technology
• Significant improvements in 3D-printing technology primary reason for market expansion
• SGLB, along with exclusive PrintRite3D software, providing game-changing technology for 3D printing

A recent report predicts that worldwide spending on 3D printing product and services will hit $15.8 billion in 2020, increasing to $35.6 billion in 2024 (http://ibn.fm/JLbIZ). That significant increase comes primarily from improvements in 3D printer technology and expansion of available materials. Sigma Labs Inc. (NASDAQ: SGLB) is leading the charge for 3D printing improvements through its proprietary PrintRite3D® software.

One industry in particular that is closely evaluating the potential for 3D metal printing is auto making, according to a recent Industry Week article (http://ibn.fm/LRpCA). “One of the most urgent transportation demands is the need for more electric vehicles to lower emissions and move people quickly and efficiently,” the article states. “Volkswagen who is among the leaders with the ID.3 – the automaker’s first mass-market electric vehicle – will eventually utilize 3D printed components. More broadly, many major automakers, including BMW [and] Jaguar Land Rover, are also piloting or deploying 3D printing technology to trim vehicle weights, speed parts production and reduce costs.”

The article points to significant improvements in 3D printing technology as a key reason for this market expansion into the world of cars, including higher parts quality and manufacturing-grade accuracy and repeatability. “In addition, 3D printing solution providers are using machine learning (ML) for heightened process control,” the article reported. “All of this has resulted in significantly better Overall Equipment Effectiveness (OEE) and larger addressable markets.”

For the auto industry to embrace 3D printing in the manufacturing of vehicles, the 3D metal-printing industry must be able to increase production speed and quality yields as well as decrease the excessive cost of quality control. To do that, parts need to be inspected and certified during the manufacturing process rather than after, which is currently the process. In addition to recognizing real-time, quality-control problems during the manufacturing process, viable technology must allow machine operators to stop the printing process and implement repairs.

That is exactly what SGLB’s PrintRite3D software does, enabling both real-time, in-process detection of quality-control manufacturing irregularities and then providing the operator with actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality-control process for the manufacture of 3D- printed-metal components.

The software could be a game changer for the world of auto making, where one vehicle – a self-driving bus named Olli – is entirely 3D printed and is capable of transporting about eight people and reaching peak speeds of 25 mph while going up to 100 miles on a single charge, according to the Industry Week article. “Olli is no speed demon, to be sure, but it has successfully demonstrated the ability of 3D printers to produce strong, lightweight components for road-worthy use cases.

“So much is occurring in the auto industry that it’s not difficult to predict automakers will continue to unlock opportunities for using metal and plastic 3D printing systems next year,” the article concluded. “In fact, a recent ARC report projects the automotive 3D printing market will experience a compound annual growth rate (CAGR) of 24.6% through 2026, when it will be worth $3.9 billion.”

Sigma Labs’ flagship PrintRite3D software is a recognized game changer in the disruptive technologies poised to transform the nascent 3D-printing industry, enabling more rapid commercial applications and growth at scale. Though with a current valuation of only about $15 million, Sigma Labs Inc. is a convincing platform from which to launch into the rapidly growing 3D-printing market.

For more information, visit the company’s website at www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Jerrick Media Holdings Inc. (JMDA) CEO Details Performance, Progress and Launch of “Challenges” Feature in Weekly Update

Jerrick Media Holdings (OTC: JMDA), a holding company that gives technology products the resources and opportunities to make ideas a reality, recently published a weekly update from the company’s CEO Jeremy Frommer. In the update, Frommer discussed the company’s stock performance as it gets closer to the uplist and its progress on multiple fronts, including its recent launch of the “Challenges” feature on Vocal, the company’s digital publishing platform. “The biggest news of the week was our introduction of the Challenges feature on the platform. With Challenges, Creators can enter multiple themed story contests each month for the chance to win cash prizes and other rewards,” Frommer states in the update. “It’s worth reiterating what it is about Challenges that is so transformative to our business. Core to Vocal’s unique value proposition for creators is its ability to provide a non-interruptive, ad-free environment in which creators can publish and share their content. Brands are similarly compelled to work with Vocal for Brands, attracted by the proven merits of branded storytelling, which fosters a far more authentic and engaging experience than its display ad predecessors. Now, Vocal will partner with brands and organizations to deliver sponsored Challenges that drive brand awareness and engagement. In doing so, we’re giving brands the ability to tap into Vocal’s network of over 500,000 content creators and encourage them to interact with, learn about and promote their brand while benefiting from the peace of mind inherent to Vocal’s brand-safe, moderated and curated environment. Brand-sponsored Challenges will effectively yield a collection of crowdsourced branded content for brands and help them reach a wider audience.”

To view the full update, visit http://ibn.fm/IGfWU

About Jerrick

Jerrick is a holding company that develops technology-based solutions. Its flagship product Vocal is a long-form, digital publishing platform focused on supporting content creators by providing them with publishing tools and monetization features that are embedded within digital communities. Vocal is architected to enable targeted marketing of branded content and e-commerce opportunities embedded within long-form content. Vocal’s community sites are managed by a dedicated team, whose primary focus is on creating safe communities and identifying monetization opportunities within them. For more information, visit the company’s website at https://Jerrick.media.

NOTE TO INVESTORS: The latest news and updates relating to JMDA are available in the company’s newsroom at http://ibn.fm/JMDA

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Closes $8M At-The-Market Offering

Genprex (NASDAQ: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced the closing of its common stock offering priced at-the-market under Nasdaq rules. Genprex sold a total of 7,620,000 shares of its common stock at a price of $1.05 each, resulting in total gross proceeds of $8 million before deducting commissions and estimated offering expenses. The company plans to use the proceeds toward the advancement of its lead clinical programs in non-small cell lung cancer (“NSCLC”) and for working capital and general corporate purposes. A.G.P./Alliance Global Partners served as the lead placement agent for the offering, and Joseph Gunnar & Co., LLC served as co-placement agent for the offering. A prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at www.SEC.gov. “The successful closing of this transaction is further evidence that our corporate vision and proprietary technology in the gene therapy cancer treatment market are gaining traction with institutional investors,” Genprex CEO Rodney Varner stated in the news release. “This offering significantly improves our balance sheet and allows us the financial flexibility to further develop our pipeline and advance our clinical trials in NSCLC for our lead drug candidate, Oncoprex, in combination with already approved lung cancer therapies. We are excited to generate additional clinical data in NSCLC from Oncoprex’s novel mechanisms of action.”

To view the full press release, visit http://ibn.fm/1Wmpr

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform. Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. The company’s lead product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (“NSCLC”), has a multimodal mechanism of action whereby it has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells, re-establish pathways for apoptosis, or programmed cell death, in cancer cells, and modulate the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. In January 2020, the FDA granted Fast Track Designation for Oncoprex(TM) imunogene therapy for NSCLC in combination therapy with AstraZeneca’s Tagrisso(R). For more information, please visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Sigma Labs, Inc. (NASDAQ:SGLB) Enters Agreement for Private Placement of Convertible Preferred Stock and Warrants

Sigma Labs (NASDAQ:SGLB), a leading developer of quality assurance software for the commercial 3D printing industry, today announced its entry into a securities purchase agreement with certain institutional investors for the purchase of shares of a new series of its preferred stock, warrants to purchase its common stock and warrants to purchase such preferred stock for total gross cash proceeds of $1.5 million to Sigma Labs. According to the update, SGLB could also receive $6 million of gross proceeds if the warrants to purchase preferred stock are exercised in full for cash, and the Company has the right to force the exercise of up to $500,000 of such warrants, subject to certain equity conditions. “The evidence is mounting that the Additive Manufacturing industry is accelerating towards wider adoption and commercialization in concert with the market’s validation of our technology,” Sigma Labs Executive Chairman Mark Ruport said in the news release. “In order to capitalize on the momentum and generate increasing revenue starting in 2020, we felt that it was imperative for the Company to strengthen its balance sheet and enter into agreements that could provide substantial additional capital going forward. Based on these agreements, we intend to extend our reach and continue to build meaningful, and mutually beneficial, relationships with leading 3D printer manufacturers, enterprise end-users, Research & Development organizations and AM software manufacturers. It’s an exciting time and I look forward to providing a comprehensive update on our progress in our year-end conference call in March.”

To view the full press release, visit http://ibn.fm/oVM50

About Sigma Labs

Sigma Labs, Inc. (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D printing industry under the PrintRite3D(R) brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (CAI) solutions known as PrintRite3D(R) for 3D advanced manufacturing technologies. Sigma Labs’ advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance mid-production, uniquely allowing errors to be corrected in real-time. For more information, please visit www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

SRAX Inc. (NASDAQ: SRAX) Rewards Social Media Users for Data as Other Platforms Lose Millions of Users in Privacy Backlash

• Recent data-privacy concerns cause social media backlash, result in millions of lost users
• SRAX enables users to earn compensation for sharing data, creates reliable data sets marketers can access
• Company recently partnered with Indian firm, facilitating entry into growing digital-ad market valued at $3.6 billion

The refusal of Facebook to revise its tracking practices (http://ibn.fm/hOtF9), along with increased concerns about data privacy, are among many reasons why the behemoth platform has decreased in popularity, losing 15 million users since 2017 (http://ibn.fm/VHHMV). SRAX Inc. (NASDAQ: SRAX) is a digital marketing and consumer data management technology company that is countering this trend through BIGtoken, its consumer managed data marketplace that enables users to own and earn from their data. The proprietary platform is giving the industry much needed user transparency and compensation, in addition to creating reliable data sets that can be sold to marketers.

Awareness among users about data privacy continues to increase as evidenced by the recent controversy caused when Facebook released a statement about refusing to change its mode of operations by use of a loophole in the California Consumer Privacy Act. Stating that its service doesn’t directly sell user data, Facebook claims it is exempt from the legislation because of its perceived function as a facilitator in the exchange of data. While Facebook’s refusal is still pending review by the Attorney General, major impacts will be experienced throughout the industry if the high court rules against the company.

SRAX addresses all these concerns and stays ahead of the curve on industry trends by giving customers the power to choose, provide and earn from their data through the company’s patented BIGtoken platform. This proprietary technology offers tools that allow users to select, approve and monetize their data while at the same time creating anonymous and reliable data sets that marketers can access for a fee. Since social media users are becoming increasingly aware of how most companies are collecting and making money from their data, SRAX offers an alternative symbiotic relationship that benefits both users and marketers.

Mounting concerns of privacy issues paralleled with increasing awareness of the BIGtoken platform has resulted in increased use of the service, currently at over 16 million users. This market shift is expected to continue while new privacy laws emerge affecting how digital marketers can reach consumers. Since BIGtoken already operates in compliance with those laws, the platform is expected to withstand changing regulations as its user base continues to grow.

Due to the transparent nature of the platform, SRAX provides relevant and accurate data that users select and share with permission. This provides SRAX with increasingly reliable data sets across many industry verticals, accurately identifying target consumers for brands and companies in the CPG, investor relations, luxury, and lifestyle spaces, keeping those brands ahead in the competitive curve with high-quality data.

SRAX is growing internationally by launching BIGtoken into several international markets through the creation of local joint ventures. The Company’s recent partnership with Mumbai-based Yash Birla Group, with diversified interests in both consumer and industrial products, will give SRAX access to India’s estimated digital population of 627 million. One of the largest growing digital ad markets in the world, India has an estimated value of $3.6 billion, with expectations to grow at a compound annual growth rate of 32%.

SRAX Mexico, with a team of 90 employees and 70 engineers, is also at the forefront of the Company’s expansion, along with plans for BIGtoken Europe to offer the platform in multiple languages in the future.

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – GP Solutions, Inc.’s (GWPD) “Prolific” Allows Beginners to Professionals to Grow Clean, Nutrient-Dense Fruits and Vegetables

GP Solutions (OTC: GWPD), the developer of “GrowPods” – controlled environment automated micro-farms, announced that Prolific products, its line of innovative nutrients and growth mediums, are now available on Amazon. Previously available solely to commercial growers, the smaller sized packages allow consumers to grow clean, uncontaminated food of the highest quality. “Prolific is perfect for growing organic vegetables and herbs in any environment, including indoor or outdoor farms, greenhouses, potted plants, and shipping containers,” GP Solutions President George Natzic said in the news release. “These innovative products are suitable for beginners to professional farmers, and anyone who wants to grow own organic superfoods.”

To view the full press release, visit http://ibn.fm/aTuEo

About GP Solutions, Inc.

GP Solutions, Inc. is the developer of highly innovative automated micro-farms trade named “GrowPods.” GrowPods are a modular, stackable and mobile vertical growing environment specifically engineered to maximize yield and automation. Offering fully insulated, food-grade shipping container that has been specifically modified to provide the optimum controlled environment for growing a wide range of horticultural and agricultural products in all environments and climates. With the company’s combination of hydroponic and certified organic soil systems, clients can produce a significantly higher yield that grows faster, healthier and more consistent. For more information, visit the company’s website at www.GrowPodSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to GWPD are available in the company’s newsroom at http://ibn.fm/GWPD

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html